Daily startup funding roundup: biosecurity, semiconductors, and AI workflows attract capital
Today's startup funding includes a mix of sectors: Puxi Optoelectronics raised a Series C for extreme-temperature power chips, Kasvu Therapeutics secured €30 million for neuroplasticity drugs, and Pilgrim raised $25 million for airborne biological-threat detection. Other deals include 50skills for AI HR, ByteAsk for coding agents, and Clastix for Kubernetes infrastructure. The total disclosed funding across selected companies includes $31.4 million in dollar rounds, €53.2 million in euro rounds, and additional yuan and yen amounts.
The geographic spread shows capital flowing across three continents, with European firms accounting for half of the ten disclosed deals. Asian startups, particularly in China's semiconductor space, attracted the largest individual rounds, while US-based Pilgrim's $25 million raise at a $150 million valuation marked the most prominent early-stage valuation.
Several rounds target infrastructure layers rather than end-user applications. Clastix's Kubernetes work and Langxi's processor-adjacent components both serve the compute demands of large AI deployments. Healthcare deals, including Kasvu's neuroplasticity research and Prevision Medicine's tumor-based diagnostics, emphasize proprietary clinical data as a competitive moat.
The funding pattern suggests investors are favoring defensible assets over easily replicated AI applications. If this trend persists, companies holding specialized physical infrastructure, proprietary clinical datasets, or deep domain expertise may attract disproportionate capital, potentially accelerating consolidation in semiconductors, biotech, and enterprise software. Consumers could ultimately benefit from more resilient supply chains and faster drug development, though smaller startups lacking such moats may find fundraising increasingly difficult as capital concentrates in fewer, better-protected ventures.